02190.HK
Zylox-Tonbridge Medical Technology Co., Ltd.
HKSE · Healthcare · Medical - Devices · CN
HKD 22.00
+2.90%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.1B | 1.1B | 782.5M | 527.8M | 334.1M |
| Cost of Revenue | 577.9M | 294.6M | 222.6M | 142.8M | 81.4M |
| Gross Profit | 1.5B | 762.9M | 559.9M | 385.0M | 252.7M |
| Operating Expenses | |||||
| R&D Expense | 483.4M | 246.8M | 233.2M | 261.0M | 233.5M |
| SG&A Expense | 637.7M | 315.9M | 265.8M | 277.9M | 249.5M |
| General & Admin Expense | 233.2M | 121.2M | 91.0M | 114.1M | 109.3M |
| Selling & Marketing Expense | 404.5M | 194.7M | 174.7M | 163.8M | 140.1M |
| Other Expenses | 59.2M | — | 44.0K | 2.6M | (8.1M) |
| Total Operating Expenses | 1.2B | 562.6M | 499.0M | 541.5M | 474.9M |
| Cost and Expenses | 1.8B | 857.2M | 721.6M | 684.3M | 542.5M |
| Operating Income (EBIT) | 337.9M | 196.6M | 60.9M | (156.5M) | (208.4M) |
| Non-Operating | |||||
| Interest Income | 102.6M | 54.6M | 67.3M | 79.0M | 95.6M |
| Interest Expense | — | 996.5K | 2.2M | 1.3M | 722.0K |
| Net Interest Income | 102.6M | 53.6M | 65.2M | 77.8M | 94.8M |
| Other Non-Op Income/Expense | 128.1M | 34.0M | 39.3M | 77.8M | 94.8M |
| Non-Operating Income (excl Interest) | (25.1M) | — | 24.7M | (79.0M) | 15.1M |
| EBT (Pre-Tax Income) | 466.0M | 230.6M | 100.3M | (78.7M) | (113.6M) |
| Income Tax Expense | 17.4M | (7.4M) | — | — | 6.9M |
| Bottom Line | |||||
| Net Income | 455.4M | 244.4M | 100.3M | (78.7M) | (113.6M) |
| Earnings from Cont. Ops | 452.8M | 244.4M | 100.3M | (78.7M) | (113.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 455.0M | 244.4M | 100.3M | (78.7M) | (113.6M) |
| Per Share | |||||
| Basic EPS | HK$1.41 | HK$0.76 | HK$0.31 | (HK$0.24) | (HK$0.34) |
| Diluted EPS | HK$1.41 | HK$0.76 | HK$0.31 | (HK$0.24) | (HK$0.34) |
| Revenue Per Share | HK$6.60 | HK$3.27 | HK$2.42 | HK$1.61 | HK$1.01 |
| Shares | |||||
| Basic Shares Outstanding | 317.5M | 323.6M | 323.3M | 328.7M | 330.4M |
| Diluted Shares Outstanding | 319.5M | 323.6M | 328.0M | 328.7M | 330.4M |
| Profitability Metrics | |||||
| EBITDA | 429.3M | 231.9M | 65.3M | (41.6M) | (86.6M) |
| D&A | 63.1M | 33.1M | 29.1M | 35.9M | 26.3M |
| EBIT | 365.8M | 198.8M | 36.2M | (77.5M) | (112.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026